The MHRA have approved lecanemab for some people with early-stage Alzheimer’s disease. However NICE does not recommend use on the NHS for any patients.

Alzheimer’s Society responds to the publication of the Memory Services Spotlight Audit 2023-24, conducted by the Royal College of Psychiatrists as part of the National Audit of Dementia.

The updated Lancet Commission study, which was part funded by Alzheimer's Society, has identified two new risk factors for dementia: untreated vision loss and high low-density lipoprotein (LDL)/bad cholesterol.  

New research reported today (Wednesday 31 July) at the Alzheimer’s Association International Conference 2024 suggests that eating processed red meat could be a significant risk factor for dementia.

Our Policy Manager responds to the UK Government's decision to delay the social care costs cap.

Today (26 July), the European Union’s drugs regulator, the Committee for Medicinal Products for Human Use (CHMP), has advised that the drug lecanemab, a treatment for Alzheimer’s disease, should not be approved for use in the EU.